- XEN901 is a potent, selective Nav1.6 inhibitor for the treatment of rare infantile epileptic encephalopathies and other forms of epilepsy. XEN901 has demonstrated efficacy against seizures in an animal model of Nav1.6 gain-of-function SCN8A epilepsy as well as models that support the treatment of adult partial onset epilepsy. Xenon expects to file an investigational new drug (IND), or IND equivalent, application in the fourth quarter of 2017.
Catalyst
Slingshot members are tracking this event:
Xenon Pharma (XENE) Expected to file an investigational new drug (IND) application or XEN901, a selective inhibitor of Nav1.6 for the treatment of epilepsy disorders in the first half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| XENE | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 04, 2017
Occurred Source:
http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2320930
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Xen901, Nav1.6, Eplilepsy, Gdc-0310
